Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New contact lens aims to slow Kids' nearsightedness

NCT ID NCT07462897

Disease control Sponsor: Essilor International Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new type of eyeglass lens designed to slow down nearsightedness (myopia) in children aged 6 to 14. The new lens is compared to an older version to see which works better. Each child will wear both lenses over a year, and researchers will measure eye growth and vision changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 76 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 14 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Refractive error in spherical equivalent (SE) ≤ -0.5 D and ≥ -4.5 D on each eye (autorefraction under cycloplegia) * Astigmatism ≤ 2.00 D for each eye * Anisometropia (difference in SE between the 2 eyes) ≤ 1.00 D * Corrected maximum distance visual acuity in each eye≥ 8/10 (equivalent to +0.1 LogMAR) * Written consent of the 2 holders of parental authority (or only one in the case of exclusive parental authority) and agreement of the participant Exclusion Criteria: * Past or current use of any type of myopic control solution (braking lenses, atropine, orthokeratology, multifocal contact lenses, etc * Strabismus (in the test of masking near or far with the best correction) * Amblyopia * Any ocular or systemic condition known to affect refractive status (e.g., keratoconus, diabetes, Down syndrome, etc.) * Presence of trauma in at least one eye - Presence of inflammatory pathologies in at least one eye * History of intraocular surgery (cataracts, filtering surgery, intravitreal surgery) in at least one eye * Past or current use of growth hormones * Use of ocular or systemic drugs that, in the opinion of the investigator, may significantly affect pupil size, accommodation, or refractive status. * Wearing contact lenses * Allergy or intolerance to cycloplegic eye drops (cyclopentolate 0.5%) * Known allergy or intolerance to eyeglass frame materials * Children with specific visual disorders requiring personalized treatments other than conventional corrective lenses. * Intolerance to conventional optical corrections * Lack of cooperation in wearing corrective lenses

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myopia progression are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myopia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myopia progression

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Département d'Ophtalmologie, Hôpital Fondation Adolphe de Rothschild

    RECRUITING

    Paris, 75019, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.